Earlier pegcetacoplan treatment preserved twice as much retinal tissue compared to delayed treatment in patients with geographic atrophy (GA) secondary to age-related macular dege ...
CervoMed's neflamapimod capsules show increased efficacy in treating dementia with Lewy bodies, with promising safety results and lower fall incidence. The new capsules led to higher plasma ...
ZURICH, SWITZERLAND / ACCESSWIRE / March 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...
22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher ...
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled 21 ...
Galderma announces positive data from OLYMPIA open-label extension study of Nemluvio in moderate-to-severe prurigo nodularis: Zug, Switzerland Monday, March 2, 2026, 15:00 Hrs [IS ...
SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results